(CercleFinance.com) – TME Pharma announced on Wednesday that a study had shown that 83% of patients with glioblastoma, a brain cancer, were still alive after 15 months of treatment, “unheard of” according to the company. biotechnology.
According to the company, five out of six patients treated with a therapeutic combination combining its NOX-A12, radiotherapy and Avastin from Roche, were alive after 15 months of testing.
For reference, the expected median overall survival for patients under current standards of care, with tumors refractory to chemotherapy and whose tumor remains detectable after surgery, is approximately 10 months.
“As long as the treatment or follow-up of these patients is ongoing, the median overall survival (mOS) will continue to improve,” adds the biotech.
Glioblastoma, considered the most serious type of brain tumor, is becoming more common in older people as the population ages.
From TME’s point of view, this combination could therefore provide a ‘clinically significant’ improvement compared to current standards in this difficult indication, with an extremely critical prognosis.
The company believes that it is in the process of establishing an ‘attractive’ clinical profile around its flagship asset, in view of the establishment of a possible partnership and future discussions with regulatory authorities regarding future market access.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
